EPAWAY

Welcome to the Brand page for “EPAWAY”, which is offered here for Pharmaceutical preparations for treating von willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant dna technology for the treatment of hemophilia, pharmaceutical preparations derived from recombinant dna technology for the treatment of hemophilia; blood products for the treatment of hemophilia, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, cells for medical or clinical use; cell cultures for medical purposes, living cells for medical use; cell cultures for medical purposes, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; pharmaceutical preparations for the treatment of respiratory conditions, antibody for the treatment of acute respiratory distress syndrome (ards), antibody for the treatment of idiopathic pulmonary fibrosis (ipf), and interstitial lung diseases (ild); pharmaceutical preparations, antibody for the treatment of hereditary angioedema, (hae);.

Its status is currently believed to be active. Its class is unavailable. “EPAWAY” is believed to be currently owned by “CSL BEHRING GMBH”.